Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025
Savara Inc. (SVRA) announced the acceptance of two posters for presentation at the American Thoracic Society (ATS) International Conference in May 2025. The presentations will showcase new data from the Phase 3 IMPALA-2 trial of Molgramostim inhalation solution for treating autoimmune Pulmonary Alveolar Proteinosis (aPAP).
The first poster will present results showing how Molgramostim reduces surfactant burden and whole lung lavage procedures in aPAP patients. The second poster will discuss the treatment's effects on respiratory health-related quality of life and patient-reported outcomes. Both abstracts will be published in the American Journal of Respiratory and Critical Care Medicine.
Additionally, Savara will host an Industry Theater session titled 'Advances in Autoimmune Pulmonary Alveolar Proteinosis' featuring experts Dr. Bruce Trapnell and Dr. Cormac McCarthy, who will discuss aPAP's pathophysiology, symptoms, diagnosis, and management.
Savara Inc. (SVRA) ha annunciato l'accettazione di due poster per la presentazione alla Conferenza Internazionale della Società Toracica Americana (ATS) a maggio 2025. Le presentazioni metteranno in evidenza nuovi dati dal trial di Fase 3 IMPALA-2 della soluzione inalatoria di Molgramostim per il trattamento della Proteinosi Alveolare Autoimmune (aPAP).
Il primo poster presenterà risultati che mostrano come il Molgramostim riduca il carico di surfattante e le procedure di lavaggio polmonare totale nei pazienti con aPAP. Il secondo poster discuterà gli effetti del trattamento sulla qualità della vita legata alla salute respiratoria e sugli esiti riportati dai pazienti. Entrambi gli abstract saranno pubblicati nell'American Journal of Respiratory and Critical Care Medicine.
Inoltre, Savara ospiterà una sessione dell'Industry Theater intitolata 'Avanzamenti nella Proteinosi Alveolare Autoimmune', con esperti come il Dr. Bruce Trapnell e il Dr. Cormac McCarthy, che discuteranno la fisiopatologia, i sintomi, la diagnosi e la gestione dell'aPAP.
Savara Inc. (SVRA) anunció la aceptación de dos carteles para su presentación en la Conferencia Internacional de la Sociedad Torácica Americana (ATS) en mayo de 2025. Las presentaciones mostrarán nuevos datos del ensayo de Fase 3 IMPALA-2 de la solución de inhalación de Molgramostim para el tratamiento de la Proteinosis Alveolar Autoinmune (aPAP).
El primer cartel presentará resultados que muestran cómo el Molgramostim reduce la carga de surfactante y los procedimientos de lavado pulmonar total en pacientes con aPAP. El segundo cartel discutirá los efectos del tratamiento en la calidad de vida relacionada con la salud respiratoria y los resultados reportados por los pacientes. Ambos resúmenes se publicarán en el American Journal of Respiratory and Critical Care Medicine.
Además, Savara llevará a cabo una sesión del Industry Theater titulada 'Avances en la Proteinosis Alveolar Autoinmune', con los expertos Dr. Bruce Trapnell y Dr. Cormac McCarthy, quienes discutirán la fisiopatología, los síntomas, el diagnóstico y el manejo del aPAP.
사바라 주식회사 (SVRA)는 2025년 5월에 열리는 미국 호흡기 학회 (ATS) 국제 회의에서 발표할 두 개의 포스터가 수락되었음을 발표했습니다. 이 발표는 자가면역 폐포 단백질증 (aPAP) 치료를 위한 몰그램오스팀 흡입 용액의 3상 IMPALA-2 시험의 새로운 데이터를 보여줄 것입니다.
첫 번째 포스터는 몰그램오스팀이 aPAP 환자의 계면활성제 부담과 전체 폐 세척 절차를 어떻게 줄이는지를 보여주는 결과를 발표할 것입니다. 두 번째 포스터는 치료가 호흡기 건강 관련 삶의 질과 환자가 보고한 결과에 미치는 영향을 논의할 것입니다. 두 초록은 American Journal of Respiratory and Critical Care Medicine에 게재될 예정입니다.
또한, 사바라는 '자가면역 폐포 단백질증의 발전'이라는 제목의 Industry Theater 세션을 개최할 예정이며, 전문가인 브루스 트랩넬 박사와 코맥 맥카시 박사가 aPAP의 병리생리학, 증상, 진단 및 관리에 대해 논의할 것입니다.
Savara Inc. (SVRA) a annoncé l'acceptation de deux affiches pour présentation lors de la Conférence Internationale de la Société Thoracique Américaine (ATS) en mai 2025. Les présentations mettront en avant de nouvelles données de l'essai de Phase 3 IMPALA-2 de la solution d'inhalation de Molgramostim pour le traitement de la Protéinose Alvéolaire Auto-immune (aPAP).
La première affiche présentera des résultats montrant comment le Molgramostim réduit la charge de surfactant et les procédures de lavage pulmonaire total chez les patients atteints d'aPAP. La deuxième affiche discutera des effets du traitement sur la qualité de vie liée à la santé respiratoire et des résultats rapportés par les patients. Les deux résumés seront publiés dans l'American Journal of Respiratory and Critical Care Medicine.
De plus, Savara organisera une session de l'Industry Theater intitulée 'Avancées dans la Protéinose Alvéolaire Auto-immune' avec les experts Dr. Bruce Trapnell et Dr. Cormac McCarthy, qui discuteront de la physiopathologie, des symptômes, du diagnostic et de la gestion de l'aPAP.
Savara Inc. (SVRA) hat die Annahme von zwei Postern für die Präsentation auf der American Thoracic Society (ATS) International Conference im Mai 2025 bekannt gegeben. Die Präsentationen werden neue Daten aus der Phase 3 IMPALA-2 Studie zur Inhalationslösung von Molgramostim zur Behandlung der Autoimmunen Alveolären Proteinosis (aPAP) präsentieren.
Das erste Poster wird Ergebnisse zeigen, die darstellen, wie Molgramostim die Surfactant-Belastung und die gesamten Lungenlavage-Verfahren bei aPAP-Patienten reduziert. Das zweite Poster wird die Auswirkungen der Behandlung auf die gesundheitsbezogene Lebensqualität der Atemwege und die von den Patienten berichteten Ergebnisse erörtern. Beide Abstracts werden im American Journal of Respiratory and Critical Care Medicine veröffentlicht.
Darüber hinaus wird Savara eine Industry Theater-Session mit dem Titel 'Fortschritte in der Autoimmunen Alveolären Proteinosis' veranstalten, in der die Experten Dr. Bruce Trapnell und Dr. Cormac McCarthy die Pathophysiologie, Symptome, Diagnose und Behandlung von aPAP erörtern werden.
- Phase 3 IMPALA-2 trial demonstrated reduction in surfactant burden
- Treatment showed decrease in required whole lung lavage procedures
- Study revealed improvements in patient quality of life outcomes
- None.
-- Company to Host Industry Theater on aPAP with Two World-Renowned Experts --
ATS 2025 Posters
Poster Title: Molgramostim Reduces Surfactant Burden and Number of Whole Lung Lavage Procedures in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results From the IMPALA-2 Phase 3 Clinical Trial
Session Title: A24 - Updates in Rare Lung Disease, Sarcoidosis, and Lung Transplant
Date/Time of Poster Discussion Session: Sunday, May 18, 2025, 9:15 - 11:15 AM PT
Location: PD05
Presenter: Tisha S. Wang, M.D., Professor of Clinical Medicine, Senior Executive Clinical Vice Chair, University of California Los Angeles Department of Medicine
Poster Title: The Effects of Molgramostim on Respiratory Health-related Quality of Life and Patient-reported Outcomes in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Session Title: A49 - Hot Topics in Rare Lung Disease
Date/Time of Poster Presentation Session: Sunday, May 18, 2025, 11:30 AM PT - 1:15 PM PT
Location: TP22
Presenter: Ali Ataya, M.D., Associate Professor of Medicine, University of
The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine on May 1, 2025. For more details about the ATS International Conference please visit their website.
Following the sessions, the posters will be available on the Congresses & Publications page of the Company’s corporate website.
ATS Industry Theater
Title: Advances in Autoimmune Pulmonary Alveolar Proteinosis
Date/Time: Tuesday, May 20, 2025, 1:00 - 2:00 PM PT
Location: Innovation Theater 3, Moscone Center Exhibit Hall in
Bruce Trapnell, M.D. and Cormac McCarthy, M.D., Ph.D. will provide an update on aPAP, including the pathophysiology of this rare lung disease, its signs and symptoms, the burden of illness, and the diagnosis and management of the disease.
About Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
aPAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in aPAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas exchange, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long-term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant.
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution (molgramostim), is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com and LinkedIn.
Forward-Looking Statements
Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Savara may not actually achieve any of the matters referred to in such forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon Savara’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risks associated with our ability to successfully develop, obtain regulatory approval for, and commercialize molgramostim for aPAP; the actions and decisions of regulatory authorities; the risks and uncertainties related to the impact of widespread health concerns or changing economic or geopolitical conditions; the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations; the availability of sufficient resources for Savara’s operations and to conduct or continue planned clinical development programs; and the timing and ability of Savara to raise additional capital as needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the SEC including our recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317308837/en/
Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
ir@savarapharma.com
Source: Savara Inc.
FAQ
What are the key findings from Savara's IMPALA-2 Phase 3 trial for SVRA's Molgramostim?
When will Savara (SVRA) present its IMPALA-2 trial results at ATS 2025?
What aspects of patient outcomes will be covered in SVRA's second poster presentation?
When will the IMPALA-2 trial abstracts be published for Savara's aPAP treatment?
